CNPR FDA Regulations 5 — Questions and Answers
Question 1: The Hatch-Waxman Act of 1984 created what important balance in pharmaceutical regulation?
- Balance between federal and state drug regulation
- Balance between encouraging generic drug competition and protecting brand-name drug innovation through exclusivity periods (Correct answer)
- Balance between prescription and OTC drug availability
- Balance between domestic and imported drug standards
Correct answer: Balance between encouraging generic drug competition and protecting brand-name drug innovation through exclusivity periods
The Hatch-Waxman Act simultaneously made generic drug approval easier via ANDAs while granting brand-name drugs market exclusivity periods to recoup R&D investment.
Question 2: Under FDA regulations, which of the following statements about comparative advertising claims is correct?
- Comparative claims are prohibited in all pharmaceutical advertising
- Comparative claims must be truthful, fairly balanced, and supported by substantial evidence (Correct answer)
- Comparative claims only require anecdotal physician testimonials for support
- Comparative claims are only allowed in direct-to-consumer advertising
Correct answer: Comparative claims must be truthful, fairly balanced, and supported by substantial evidence
Comparative claims in pharmaceutical advertising are permitted but must be based on substantial evidence, presented fairly, and not mislead about the competitor product.
Question 3: What does the term 'substantial evidence' mean in the context of FDA drug approval for efficacy?
- At least one clinical study showing any positive trend
- Evidence from adequate and well-controlled investigations demonstrating the drug's effectiveness (Correct answer)
- Expert physician opinion from 50 or more specialists
- Successful use in at least 5 countries before U.S. application
Correct answer: Evidence from adequate and well-controlled investigations demonstrating the drug's effectiveness
The FDA requires substantial evidence of efficacy, typically meaning data from two adequate and well-controlled clinical trials demonstrating the drug's claimed effects.
Question 4: A pharmaceutical sales representative receives a request from a physician asking for data on using a drug for a condition not in the approved labeling. What is the appropriate response?
- Immediately provide promotional materials highlighting off-label benefits
- Decline to discuss any information about the drug
- Refer the request to medical affairs for an appropriate medical information response (Correct answer)
- Provide the data and document it as a routine sales call
Correct answer: Refer the request to medical affairs for an appropriate medical information response
Unsolicited off-label information requests should be referred to the company's Medical Affairs or Medical Information department, which can provide non-promotional scientific exchange.
Question 5: Under the Physician Payments Sunshine Act (Open Payments), pharmaceutical manufacturers must report transfers of value to physicians that exceed which threshold?
- $10 per transfer or $100 annually (Correct answer)
- $25 per transfer or $500 annually
- $50 per transfer or $1,000 annually
- $100 per transfer or $5,000 annually
Correct answer: $10 per transfer or $100 annually
Manufacturers must report payments or transfers of value to physicians exceeding $10 per transfer or $100 in aggregate annually to CMS's Open Payments database.
Question 6: What FDA enforcement action involves a company voluntarily recalling a product that poses the most serious risk of harm or death?
- Class I Recall (Correct answer)
- Class II Recall
- Class III Recall
- Market Withdrawal
Correct answer: Class I Recall
A Class I Recall is the most serious type, used when a product can cause serious adverse health consequences or death if used as labeled.
Question 7: The FDA's Office of Prescription Drug Promotion (OPDP) can issue which type of letter to demand a company immediately stop or correct misleading promotional materials?
- Warning Letter and Untitled Letter (Correct answer)
- Consent Decree and Injunction
- FDA Form 483 and Warning Letter
- Notice of Violation and Cease and Desist
Correct answer: Warning Letter and Untitled Letter
OPDP issues Warning Letters (for more serious violations) and Untitled Letters (for less serious violations) requiring companies to correct or cease misleading promotions.
CNPR FDA Regulations 5
The Hatch-Waxman Act of 1984 created what important balance in pharmaceutical regulation?